Empagliflozin and uric acid metabolism in diabetes: A post hoc analysis of the EMPA‐REG OUTCOME trial-Reference-Cited by-同舟云学术

Empagliflozin and uric acid metabolism in diabetes: A post hoc analysis of the EMPA‐REG OUTCOME trial

Published:2021-10-04 Issue:1 Volume:24 Page:135-141
ISSN:1462-8902
Container-title:Diabetes, Obesity and Metabolism
language:en
Short-container-title:Diabetes Obes Metab

Author:

Ferreira João Pedro¹²^ORCID,Inzucchi Silvio E.³^ORCID,Mattheus Michaela⁴,Meinicke Thomas⁴,Steubl Dominik⁴⁵,Wanner Christoph⁶,Zinman Bernard⁷^ORCID

Affiliation:

1. Université de Lorraine, Centre d'Investigations Cliniques Plurithématique 1433 and Inserm U1116, Centre Hospitalier Universitaire de Nancy, FCRIN INI‐CRCT (Cardiovascular and Renal Clinical Trialists) Nancy France

2. Cardiovascular Research and Development Center, Department of Surgery and Physiology, Faculty of Medicine of the University of Porto Porto Portugal

3. Section of Endocrinology, Yale School of Medicine and Yale‐New Haven Hospital New Haven Connecticut USA

4. Boehringer Ingelheim Pharma GmbH & Co KG Ingelheim Germany

5. Department of Nephrology, Faculty of Medicine Technical University Munich Munich Germany

6. Department of Medicine, Division of Nephrology Würzburg University Clinic Würzburg Germany

7. Lunenfeld‐Tanenbaum Research Institute, Mount Sinai Hospital University of Toronto Toronto Ontario Canada

Funder

Boehringer Ingelheim

Publisher

Wiley

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/dom.14559

Reference36 articles.

1. Association between uric acid levels and cardio‐renal outcomes and death in patients with type 2 diabetes: A subanalysis of EMPA‐REG OUTCOME

2. Serum Uric Acid Levels and Risk of Metabolic Syndrome: A Dose-Response Meta-Analysis of Prospective Studies

3. Serum Uric Acid Levels and Incident Chronic Kidney Disease in Patients With Type 2 Diabetes and Preserved Kidney Function

4. The Role of Uric Acid in Kidney Fibrosis: Experimental Evidences for the Causal Relationship

5. Uric acid and the cardio‐renal effects of SGLT2 inhibitors

Cited by 40 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Effects of ertugliflozin on uric acid and gout‐related outcomes in persons with type 2 diabetes and cardiovascular disease: Post hoc analyses from VERTIS CV;Diabetes, Obesity and Metabolism;2024-09-02

2. Retrospective analysis of the effect of SGLT-2 inhibitors on renal function in patients with type 2 diabetes in the real world;Frontiers in Pharmacology;2024-08-05

3. Mechanism and use strategy of uric acid-lowering drugs on coronary heart disease;IJC Heart & Vasculature;2024-08

4. Update on the clinical applications of SGLTis: Insight to benefits beyond hypoglycemic and cardiorenal protection;Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy;2024-07-08

5. SGLT2 Inhibitors, but Not GLP-1 Receptor Agonists, Reduce Incidence of Gout in People Living With Type 2 Diabetes Across the Therapeutic Spectrum;Clinical Therapeutics;2024-07